Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at William Blair in a research note issued to investors on Friday,RTT News ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Report with the AI impact on market trends - The global biotech market size is estimated to grow by USD 805.6 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Investor's Business Daily on MSN1d
How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion ChapterVertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
If you appreciate the Mercury's interesting and useful news & culture reporting, consider making a small monthly contribution ...
Big Issues Changemakers in health and disability are working to improve the lives of those marginalised by society.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback